title: A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study.
abstract: BACKGROUND
  There is renewed interest in magnetic hyperthermia as a treatment modality for cancer, especially when it is combined with other more traditional therapeutic approaches, such as the co-delivery of anticancer drugs or photodynamic therapy.
  
  
  METHODS
  The influence of bimagnetic nanoparticles (MNPs) combined with short external alternating magnetic field (AMF) exposure on the growth of subcutaneous mouse melanomas (B16-F10) was evaluated. Bimagnetic Fe/Fe3O4 core/shell nanoparticles were designed for cancer targeting after intratumoral or intravenous administration. Their inorganic center was protected against rapid biocorrosion by organic dopamine-oligoethylene glycol ligands. TCPP (4-tetracarboxyphenyl porphyrin) units were attached to the dopamine-oligoethylene glycol ligands.
  
  
  RESULTS
  The magnetic hyperthermia results obtained after intratumoral injection indicated that micromolar concentrations of iron given within the modified core-shell Fe/Fe3O4 nanoparticles caused a significant anti-tumor effect on murine B16-F10 melanoma with three short 10-minute AMF exposures. We also observed a decrease in tumor size after intravenous administration of the MNPs followed by three consecutive days of AMF exposure 24 hrs after the MNPs injection.
  
  
  CONCLUSIONS
  These results indicate that intratumoral administration of surface modified MNPs can attenuate mouse melanoma after AMF exposure. Moreover, we have found that after intravenous administration of micromolar concentrations, these MNPs are capable of causing an anti-tumor effect in a mouse melanoma model after only a short AMF exposure time. This is a clear improvement to state of the art.
authors.affiliation: Department of Anatomy and Physiology, Kansas State University, Manhattan, KS 66506, USA.
authors.forename: Sivasai
authors.initials: S
authors.lastname: Balivada
authors.forename: Raja Shekar
authors.initials: RS
authors.lastname: Rachakatla
authors.forename: Hongwang
authors.initials: H
authors.lastname: Wang
authors.forename: Thilani N
authors.initials: TN
authors.lastname: Samarakoon
authors.forename: Raj Kumar
authors.initials: RK
authors.lastname: Dani
authors.forename: Marla
authors.initials: M
authors.lastname: Pyle
authors.forename: Franklin O
authors.initials: FO
authors.lastname: Kroh
authors.forename: Brandon
authors.initials: B
authors.lastname: Walker
authors.forename: Xiaoxuan
authors.initials: X
authors.lastname: Leaym
authors.forename: Olga B
authors.initials: OB
authors.lastname: Koper
authors.forename: Masaaki
authors.initials: M
authors.lastname: Tamura
authors.forename: Viktor
authors.initials: V
authors.lastname: Chikan
authors.forename: Stefan H
authors.initials: SH
authors.lastname: Bossmann
authors.forename: Deryl L
authors.initials: DL
authors.lastname: Troyer
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000502:physiology; D005260:Female; D052203:Ferrosoferric Oxide / Q000008:administration & dosage* / Q000737:chemistry; D006979:Hyperthermia, Induced / Q000379:methods*; D007501:Iron / Q000008:administration & dosage* / Q000032:analysis; D055909:Magnetic Field Therapy / Q000379:methods*; D008546:Melanoma, Experimental / Q000473:pathology / Q000628:therapy*; D053768:Metal Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D051379:Mice; D008810:Mice, Inbred C57BL; D011166:Porphyrins / Q000008:administration & dosage / Q000737:chemistry
chemical_list: D011166:Porphyrins; C018395:tetracarboxyphenylporphine; D007501:Iron; D052203:Ferrosoferric Oxide